Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified

Thrombosis and Haemostasis

Volumn 105, Issue 5, 2011, Pages 752-759

  Serebruany, Victor L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trial; Mortality; Outcomes; Site monitoring; Ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; TICAGRELOR;

ACUTE CORONARY SYNDROME; ARTICLE; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; CORONARY ARTERY DISEASE; DRUG APPROVAL; DRUG EFFICACY; EVIDENCE BASED MEDICINE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; HUNGARY; HYPERTENSION; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; POLAND; PRIORITY JOURNAL; SELF MONITORING; SEPSIS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; UNITED STATES;

ACUTE CORONARY SYNDROME; ADENOSINE; BIAS (EPIDEMIOLOGY); CLINICAL TRIALS AS TOPIC; EUROPE; HUMANS; MORTALITY; SURVIVAL RATE; TICLOPIDINE; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79955772062     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-12-0807     Document Type: Article

References (20)

1. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2009; 361: 1045-1057.
2. Ticagrelor Secondary Review. Available at http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM220192.pdf.
3. CURE Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Eng J Med 2001; 345: 494-502.
4. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2007; 357: 2001-2015.
5. Stone GW, Ware JH, Bertrand ME, et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. J Am Med Assoc 2007; 298: 2497-2506.
6. Serebruany VL, Atar D. The PLATO trial: do you believe in magic? Eur Heart J 2010; 31: 764-767.
7. Serebruany VL. Dyspnea after AZD6140: safety first? Eur Heart J 2006; 27: 1505.
8. ISIS-2 Trial Investigators. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2: 349-360.
9. COMMIT Collaborative Group. Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 2005; 366: 1607-1621.
10. Malkin CJ, Channer KS. Life saving or life prolonging? Interpreting data from survival curves for patients with congestive heart failure. Eur J Heart Fail 2005; 7: 143-148.
11. Serebruany VL. Mortality benefit in PLATO cannot be explained by antiplatelet properties of ticagrelor. Cardiology 2011; 117: 231-233.
12. AstraZeneca initiates Brilinta Pegasus-TIMI 54 study. Available at: http://clinicaltrials.pharmaceutical-businessreview.com/news/astrazeneca_initiates_brilinta_pegasustimi_54_study_101004.
13. Husted S, van Giezen JJ. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther 2009; 27: 259-274.
14. Cannon CP, Husted S, Harrington RA, et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J Am Coll Cardiol 2007; 50: 1844-1851.
15. Pritsch M, Unnebrink K. Monitoring clinical studies. Development, measures and consequences. Med Klin (Munich) 2000; 95: 72-76.
16. Ricci S, Lewis S, Sandercock P; IST Collaborative Group. Previous use of aspirin and baseline stroke severity: an analysis of 17,850 patients in the International Stroke Trial. Stroke 2006; 37: 1737-1740.
17. Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009; 361: 2318-2329.
18. 1-receptor antagonist, in acute heart failure. N Engl J Med 2010; 363: 1419-1428.
19. Serebruany VL. Adenosine release: A potential explanation for the benefits of ticagrelor in the PLATelet inhibition and Outcomes trial. Am Heart J 2010; 161: 1-4.
20. Ruff CT, Giugliano RP, Antman EM, et al.; for the TRITON-TIMI 38 Investigators. Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world. Int J Cardiol 2011; in press.